Trump has hailed the Regeneron therapy as a cure for the virus, but the company’s CEO Leonard Schleifer was quick to point out that the scientific evidence is not there to support the claim.

Regeneron: Der Kampf um globale Gleichheit im Pharmasektor Leonard Schleifer, CEO von Regeneron, diskutiert über die unfaire ...

Regeneron CEO Dr. Leonard Schleifer added, "In 2025, we will continue to focus on our four blockbuster medicines as we progress our approximately 40 investigational candidates covering dozens of ...

Regeneron’s Co-Founder, President and CEO, Leonard Schleifer, stated: "we anticipate these enhancements will lead to an acceleration in Eylea HD uptake starting in the second half of this year." ...

CEO Leonard Schleifer highlighted 10% revenue growth ... expressed increased concerns about competitive pressures on EYLEA.

the acquisition of Checkmate will add a promising new modality to Regeneron's toolkit of potential approaches for difficult-to-treat cancers," said Leonard Schleifer, Regeneron's chief executive ...

Biotech company Regeneron (NASDAQ ... dividend program and increased share repurchase capacity," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ... Joining me on today's call are Dr. Leonard Schleifer, Board Co-Chair, Co-Founder, President and Chief Executive Officer; Dr. George Yancopoulos, ...

Regeneron Pharmaceuticals ... The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown ...